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Abstract 
The primary purpose of this study was to evaluate the impact of CYP2C8*3 and three genetic ABCB1 
variants on the elimination of paclitaxel. We studied 93 Caucasian women with ovarian cancer treated with 
paclitaxel and carboplatin. Using sparse sampling and nonlinear mixed effects modeling, the individual 
clearance of unbound paclitaxel was estimated from total plasma paclitaxel and Cremophor EL. The 
geometric mean of clearance was 385 l/h (range 176-726 l/h). Carriers of CYP2C8*3 had 11% lower 
clearance than non carriers, P=0.03. This has not been demonstrated before in similar studies; the 
explanation is probably the advantage of using both unbound paclitaxel clearance and a population of 
patients of same gender. No significant association was found for the ABCB1 variants C1236T, G2677T/A 
and C3435T. Secondarily other candidate SNPs were explored with possible associations found for 
CYP2C8*4 (P=0.04) and ABCC1 g.7356253C>G (P=0.04). 
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Introduction 
Paclitaxel is used to treat cancer of the breast, lung, ovary and other neoplasms. In ovarian cancer 
the standard of care in most clinics is post-surgery combination chemotherapy with carboplatin and 
paclitaxel. Although the initial response rate is as high as 70-85%(1), most patients with advanced 
stages eventually relapse and die of the disease. Paclitaxel is dosed normalized to body surface area 
(BSA) and in most regimes infused over 1, 3 or 24 hours. The dose limiting toxicities are neutropenia 
and neuropathy. There is a large inter-individual variability in toxicity and therapeutic effect of 
paclitaxel in ovarian cancer treatment which remains a clinically relevant problem with implications 
on survival and quality of life of the patients and practical with regard to the handling of dose delay, 
dose reduction or cessation of the treatment(2). Several possible causes of this variability have been 
suggested; especially the notion that single nucleotide polymorphisms (SNPs) in certain genes could 
cause significant changes in the affinity and/or expression of key transporters or metabolizing 
enzymes. Paclitaxel is metabolized to inactive compounds by CYP2C8 and CYP3A4 in the liver(3-5), 
and is also a substrate for the ATP driven efflux pump P-glycoprotein encoded by the ABCB1 gene(6).   
A host of other candidate genes linked to paclitaxel were picked for exploratory analysis: they 
include CYP3A5, ABCC1, ABCC2, ABCG2, ABCC10, CYP1B1 and SLCO1B3(7-13). These are all drug 
transporters except CYP3A5 which has a substrate range similar to CYP3A4, and CYP1B1 which has 
been implied to have a role in taxane metabolism and therapeutic effects(7). Transporters can 
facilitate elimination by actively transporting the drug into a metabolizing cell or by actively 
exporting drug to the bile.  
Total plasma paclitaxel elimination has previously been shown to be nonlinear(14). This has been 
attributed to saturable transport(15) and saturable binding(16) but also to paclitaxel being trapped 
in micelles formed by adjuvant Cremophor EL(17-19). Considering the unbound clearance of 
paclitaxel instead of total plasma clearance can therefore be expected to give a clearer estimate of 
the impact of genetic variants on the elimination processes.  
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The aim of the present study was to evaluate the elimination capacity of patients with the 
CYP2C8*3, ABCB1 C1236T, G2677T/A and C3435T variants in a confirmatory type analysis and other 
variants in CYP2C8 and ABCB1 as well as variants in CYP1B1, CYP3A4/5,  SLCO1B3,  ABCC1, ABCC2, 
ABCG2 and ABCC10 in an exploratory analysis. The study was initiated based on reports on 
CYP2C8*3 as having decreased paclitaxel metabolism(20;21) and reports of a functional significance 
of ABCB1 SNPs with particular interest in C1236T, G2677T/A and C3435T(22-24); the other candidate 
SNPs entered the study after it was initiated but the a priori distinction between confirmative and 
exploratory candidates was kept in order to meet the issue of multiple testing. 
We present a prospective pharmacogenetic study on the population pharmacokinetics of paclitaxel 
in 93 Scandinavian Caucasian female patients with epithelial ovarian/peritoneal cancer. 
Patients and methods 
Patients 
Eligibility criteria included: candidates for paclitaxel/carboplatin chemotherapy, clinical or 
histopathological diagnosis of epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer, 
age ≥18 years, Caucasian, WHO / ECOG performance status ≤2, no concurrent malignant diseases 
and adequate contraception for women of child-bearing potential. All patients provided written and 
verbal consent before entering the study as per Helsinki declaration. All patients were scheduled for 
six to nine courses of paclitaxel (175 mg/m2), 3 hour iv-infusion followed by carboplatin (AUC 5-6 
mg*min/ml), every third week. Paclitaxel was administered in formulation with Cremophor EL (CrEL; 
polyoxyethyleneglycerol triricinoleate 35) at 5 ml per 30 mg paclitaxel. All patients were pretreated 
with steroid and histamine receptors H1 and H2 antagonists as recommended by national 
guidelines. Concurrently used drugs were recorded and compared to known inhibitors of CYP3A4/5 
and CYP2C8. The study was approved by regional ethics committees of Southern Denmark and Lund, 
Sweden. Patients were recruited at oncology departments in Denmark and Sweden. 
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Blood sampling, paclitaxel and cremophor EL analysis 
Three consecutive samples were collected from one cycle from each patient. Plasma was sampled at 
noted time points; approximately at 3 hours (just prior to end of infusion), at 5-8 hours and at 18-24 
hours after start of paclitaxel infusion. Aliquots of whole blood for DNA extraction was kept at -20 °C 
or less. The total concentration of paclitaxel in plasma was estimated using a liquid-liquid extraction 
method and High-Performance Liquid Chromatography (HPLC) with UV detection. Paclitaxel was 
purchased from Sigma, St. Louis, MI, and docetaxel from Fluka, Buchs, CH. The extraction method 
was performed as described by Alexander et al.(25). The sample was transferred to a conical 300 l 
polypropylene HPLC micro vial. An aliquot of 40 l was injected into a LaChrom HPLC system (Merck-
Hitachi, Darmstadt, Germany) and monitored at λ= 227 nm on the UV-detector. The separation was 
performed on a 50 x 2.1 mm Gold C18 column (2.1 μm particle size) (Thermo, San Jose, CA) at 30C 
using isocratic elution. The mobile phase consisted of acetonitrile: Milli-Q water: glacial acetic acid 
(35:65:0.1 v/v %). The flow rate was 0.2 ml/min. Calibration curves ranging up to 10 000 nmol/l was 
produced for each day of analysis and showed a good linearity (r=0.997). The intraday variability was 
< 8.5 % for paclitaxel. The interday variability (n=5 days) was investigated for six concentration levels 
(75, 300, 750, 1 500, 3 500 and 8 500 nmol/l) and was < 6 % for paclitaxel.  The accuracy for 
paclitaxel ranged from 89.2 to 101.8 %. The lower limit of detection was 20 nmol/l and the lower 
limit of quantification was 25 nmol/l for paclitaxel. 
Cremophor EL concentrations were determined by an earlier described method with minor 
changes(26). The samples were analysed in duplicate with a standard curve ranging from 0.1–1.0 % 
and a spiked quality control sample. The sample concentration was interpolated from the non-linear 
standard curve by second-order polynominal regression using GraphPad Prism version 5.0a 
(GraphPad software, USA). The intra- and interday variation (C.V.) of the quality control sample was 
found to be 7.0 % and 7.4 %, respectively (n=10) and the intra- and interday accuracy (%-difference 
from the spiked ”true value”) was +1 % and -3 %, respectively. The limits of quantification were set 
by the standard curve which covered all plasma samples analysed in the study.  
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Pharmakokinetic analysis 
The clearance of unbound paclitaxel was estimated from total paclitaxel concentrations and CrEL 
concentrations in a nonlinear mixed effects analysis. This approach is described by Henningsson et 
al(27); in brief, we used a two compartment structure with total paclitaxel concentrations Cp and 
unbound concentration Cu described with the following equation: 
 
Where [CrEL] is the measured Cremophor EL concentration, Bmax = 0.2311x[AAGP]-0.017, [AAGP] is 
the measured α-acid glycoprotein concentration and Km = Bmax/9.41. Constants are the fixed 
estimates reported by Henningsson et al. The covariate model proposed by Henningsson et al(27) 
with BSA explaining IIV (inter-individual variability) of clearance and volumes of distrubution and 
bilirubin explaining IIV of unbound clearance was used without any changes as the basic model. 
Additionally age, performance status, smoking, alcohol, albumin, alkaline phosphatase and alanine 
aminotransferase were tested as covariates in a trial and error manner using likelihood ratio test in 
NONMEM. Age and performance status further explained IIV of clearance, lowering the objective 
function value (OFV) 13.5 and 18.5 points respectively. Assuming that OFV approximately is chi-
squared distributed, a true effect of the covariates seemed very likely (P-value < 0.001) and both 
were added in the final model. No other covariates significantly contributed to IIV. Empirical Bayes 
estimates of unbound clearance of paclitaxel were obtained and are herein referred to as clearance. 
All analyses were performed with the first-order conditional estimation method with interaction in 
NONMEM VI (Beal & Sheiner, University of California, San Francisco, CA) and graphical diagnostics 
were obtained using the software Xpose(28) and PsN(29). 
Genotyping procedures 
Genomic DNA was extracted from whole blood using standard methods. SNPs in CYP2C8, CYP3A4, 
SLCO1B3 (except G767C) and ABCB1(except A-1G) were determined using Pyrosequencing as 
previously described(30-32). The variants in CYP1B1, CYP3A5, ABCC1, ABCC10 and G767C in 
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SLCO1B3, A-1G in ABCB1 and rs2273697 in ABCC2 were genotyped using TaqMan® pre-designed SNP 
genotyping assays by Applied Biosystems (Foster city, CA). SNPs in ABCG2 and rs17222723 and 
rs8187710 in ABCC2 were genotyped using pairs of allele specific primers (ASP) and a locus specific 
primer (LSP) in SYBRgreen real time PCR assays. The used primers were: rs8187710 (ABCC2) ASP: 5`-
CCTAGA CAACGGGAAG ATTATAGAGTG-3´/5`-TCCTAGA CAACGGGAAG ATTATAGAGTA-3, LSP: 5’-
GCTAG AATTTTGTGC TGTTCACATT C-3’; rs17222723 (ABCC2) ASP: 5’-GCG ATTTCTGAAA 
CACAATGAGGW-3’, LSP: 5´-CCCACCGCTAA TATCAAACAT ATAGAAC-3; rs2231142 (ABCG2) ASP: 5’-
CACTCTGACGGTGAGAGAAAACTTAM-3’, LSP: 5`- GCCACTTTAT CCAGACCTAA CTCTTG-3`; 
rs2231137(ABCG2) LSP: 5’-CACCTAGTGTTTGCA ATCTCATTTATCT-3’, ASP: 5`-
CCATTGGTGTTTCCTTGTGACAY-3`. All real time assays were performed on ABI PRISM 7700 or 
StepOnePlus from Applied Biosystems(Foster city, CA). Genotype calling using SYBRgreen was 
carried out by visual assessment by two persons separately. 
ABCB1 haplotype inference 
Haplotypes of the six ABCB1 SNPs were inferred using the software package PHASE, version 2.1 by 
Stephens et al(33;34). The program infers haplotype frequencies and the most likely individual 
haplotype using a Bayesian statistical method. We ran PHASE, with default settings 10 times. All runs 
returned 100% consistent calls. The inferred population frequencies agreed well with Kroetz et al(35) 
who investigated the haplotype structure of the ABCB1 gene in 100 Caucasian from a human 
variation panel and the frequencies estimated by the EM algorithm in STATA 10 (StataCorp, Texas, 
USA). In order to test an allele dose effect the resulting 13 haplotypes (with phase information) were 
grouped into diplotype 1 to 4 based on the 1236C>T, 2677G>TA and 3435C>T SNPs in a fashion 
similar to Sissung et al(36). The “full wild-type” is thus CGC/CGC (diplotype 1) and the “full variant 
type” TTT/TTT (diplotype 3) and the heterotype CGC/TTT (diplotype 2)(Table 1). This approach can 
possibly reveal effects of interplay between cis variants and are proposed by some to add valuable 
information that is impossible to achieve by assessing the SNPs separately(37-39). 
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Statistical methods 
Logtransformed clearance was assessed visually to be approximately normal distributed and was 
used throughout the study. Geometric means are antilog of means of the log transformed data. All 
tests are two sided. For the confirmatory type analysis, P-values of 0.05 or less are considered 
statistical significant. For association testing multiple regression (trend) test was used; thus assuming 
an allele dose effect. Both raw P-values and values for the test controlled for BSA, age and 
performance status are reported; all computations were carried out using STATA 10 (StataCorp, 
Texas, USA). Inferred haplotypes in ABCB1 were tested for association to clearance using the 
software package BIMBAM version 0.99 by Servin and Stephens(40), assuming normal distribution of 
clearance; the program was run with default settings.
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Results 
Patients 
Total plasma paclitaxel and Cremophor EL concentrations were available from 93 patients. They 
were recruited from four hospital centers in Denmark: Odense 66 (71 %), Herlev 12 (13 %), Herning 7 
(8 %), Vejle 4 (4 %) and one in Sweden: Lund 4 (4 %).  Median age was 60.1 years (range, 32-79.4 
years) (Table 2). One additional patient was omitted from analysis because the 18-24 hour sample 
gave consistent results of 3172 ng/l (45-fold higher than mean) and a vial mix-up could be excluded. 
Two patients received bevacizumab from the 2nd cycle (subsequent to the plasma sampling cycle). 
Three patients used a CYP3A4/5 inhibitor prior to or during the course where PK samples were 
taken. One patient used ketoconazole, the two others used fluconazole. The individual clearance 
estimates of unbound paclitaxel for these three patients were 383 l/h, 456 l/h and 282 l/h 
respectively (Figure 1). No significant correlation between genotypes and BSA, age, bilirubin and 
performance status was found (data not shown). 
Paclitaxel pharmacokinetics 
The nonlinear mixed effects model fitted the data well as indicated by goodness-of-fit plots (not 
shown) and previous data using this model (Table 3). Overall geometric mean of clearance of 
unbound paclitaxel was 385 l/h (range 176-726 l/h). Typical estimates of compartment volumes and 
inter compartmental clearances and relative standard errors were similar to those earlier reported 
(27;41)(Table 3). The model predicts that: an increase in BSA of 0.1m2 increases the typical value of 
clearance by 6.2 %, an increase in age of 10 years decrease the typical value of clearance by 6 % and 
the typical value of clearance for patients with WHO/ECOG performance status of 0-1 was 396 l/h 
compared to 304 l/h for performance status 2. The average measured Cremophor EL concentration 
and range were 4.10 vol/vol ‰ [2.63-6.67 ‰], 3.32 vol/vol ‰ [2.25-5.81 ‰] and 2.07 vol/vol ‰ 
[1.10-3.39 ‰] for the first, second and third sampling respectively.   
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Results of genotyping and haplotype inference 
Twenty-two single nucleotide polymorphisms (SNPs) were analyzed in 10 genes. Candidate SNPs 
were split, a priori, into two groups; one for confirmative type analysis and one for exploratory 
analysis (Table 4). Allele frequencies were all similar to frequencies reported in the NCBI SNP 
database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp). The genotype distributions were all in 
Hardy-Weinberg equilibrium (numbers not shown) except CYP2C8*1B, ABCG2 (c.421C>A) rs2231142 
and CYP1B1*3 where the P-values of Pearson Chi2 statistic were 0.03, 0.05 and 0.01 respectively. 
Inferring haplotypes in ABCB1 resulted in 13 haplotypes (data not shown) with frequencies from 
0.5% to 27.4%. Frequencies were comparable with a previous report by Kroetz et al (35). 
Genotype vs. paclitaxel clearance 
The confirmative analysis: The CYP2C8*3 genotype was associated with an 11% lower clearance of 
unbound paclitaxel, which was statistically significant with a P-value of 0.03 (Figure 1). No significant 
correlation was found between clearance and ABCB1 C1236T, G2677T/A and C3435T genotypes 
(Table 4). Analysis of ABCB1 “haplotypes” performed using the BIMBAM software showed no 
association with clearance for any single SNP or any two or three SNP combination (data not shown). 
No significant association was found between diplotype group 1-3 and clearance (P-value of 0.12) 
using linear regression trend-test controlled for BSA, age and performance status (Table 1). 
Explorative analysis: seven patients with the CYP2C8*4 (c.792C>G) variant had 18% lower mean 
clearance (geometric) of unbound paclitaxel than wild-type individuals (Table 4), P-value 0.04. The 
one individual carrying both the CYP2C8*3 and *4 variant had a clearance of 270 l/h. For the intronic 
SNP in ABCC1 (rs504348) carrying one or two variant alleles were associated with 7% lower 
clearance of unbound paclitaxel, P-value 0.04. P-values for the exploratory analysis are reported 
without any correction for multiple testing and should be interpreted accordingly. 
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Discussion 
Our study tests the hypothesis that genetic variants in CYP2C8 and ABCB1 contribute to the 
observed inter-individual variability in paclitaxel clearance. We found evidence supporting a reduced 
clearance among patients carrying the CYP2C8*3 and possibly also the *4 variant. These results 
confirm the finding in a pilot study on 33 ovarian cancer patients treated in Sweden(42). To our 
knowledge this is the largest prospective study reporting this association. The results, however, are 
in somewhat contrast to Henningsson et al(43) who found no correlation between clearance and 
CYP2C8*3, CYP2C8*4 and ABCB1 C3435T in 97 patients (male and female) treated with paclitaxel 
(80-225mg/m2) and Marsh et al(44) who found no correlation between clearance and CYP2C8*3, 
CYP2C8*4, ABCB1 C1236T and ABCB1 G2677T in 93 patients with breast cancer treated with 24-hour 
paclitaxel infusion (575-775mg/m2). This discrepancy can be explained by chance or: in case of the 
study by Henningsson et al, by gender in so far that Joerger et al(45) demonstrated a 20 % higher 
elimination of paclitaxel in males than in females, and in the case of the study by Marsh et al by the 
nonlinear elimination of paclitaxel reported in the studied population(46). In the pilot study of 33 
patients(42), the rare genotype 2677GA was associated with increased  clearance of paclitaxel 
compared to 2677TT and 2677GG. In the present study five patients carried the 2677A allele but 
although the patient with the highest clearance among all patients (726 l/h) carried this allele no 
significant association was found in this study (data not shown). Baker et al(47) studied docetaxel in 
92 patients and found no correlation between docetaxel clearance and ABCB1, ABCC2 and SLCO1B3 
variants, but they did report a 64% increase in clearance for the simultaneous presence of 
CYP3A4*1B and CYP3A5*1A. This finding was not replicated in our study (data not shown). 
 In the exploratory analysis a possible association between an intronic SNP in ABCC1 (rs504348) and 
clearance was found. To our knowledge this has not been reported in the literature before. 
However, replication in future studies are warranted before any conclusions can be made regarding 
this association because the multiple testing makes a spurious finding more likely. The only support 
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in the literature is contradicting evidence supporting a role of ABCC1 in taxane metabolism in 
vitro(48;49) and a single report of a possible relationship to a clinical (in vivo) outcome(50). The 
geometric mean of paclitaxel clearances across diplotype 1-3 is 399, 381 and 355 l/h which suggest a 
trend; however it did not reach the level of statistical significance (P-value 0.12). 
While not the aim of the study, our results support the finding by Joerger et al(45) that age is 
negatively correlated and BSA positively correlated to paclitaxel clearance; the 11 % decrease in 
clearance of unbound paclitaxel explained by CYP2C8 variant is comparable in size to the effects of 
gender (20 %, male > female), age (-11 % per 20 years) and BSA (11 % per 0.2m2) reported by Joerger 
et al. Somewhat surprisingly the patients´ performance status seem to have strong negative impact 
on the clearance; mean clearance and 10th and 90th percentiles observed were 397 l/h [300;490 l/h] 
and 291 l/h [176;468 l/h] for performance status 0-1 and 2 respectively. This impact on clearance of 
a “non-fixed” variable provides a competing and dynamic biological explanation for clearance that 
certainly should be controlled for in the analysis. Omitting patients with performance status 2 from 
analyses like this might provide a clearer signal, but on the other hand information about an 
important subgroup would be lost. Although we did find an association between CYP2C8*3 and 
clearance of unbound paclitaxel, and causality of the association is scientifically plausible - the 
magnitude of the effect (i.e. approximately 11%) is somewhat disappointing. Even if we assume that 
the clearance is tightly correlated to the efficacy or toxicity of paclitaxel – genotyping for CYP2C8*3 
in clinical practice is not rational at this point in time because the effect is too small. The variability is 
likely explained by multiple small effect factors both genetic and environmental. It can be speculated 
that if individualized treatment with paclitaxel is to become a reality in the future and CYP2C8*3 
genotyping is to play a role therein it must be in combination with multiple other factors. 
In conclusion the study provides evidence supporting a contribution from the CYP2C8*3 variant and 
possibly also the CYP2C8*4 and ABCC1 (rs504348) variants to the variability of paclitaxel clearance. 
In future studies (of paclitaxel) it might be worthwhile to consider pooling patients with the 
CYP2C8*3 and *4 variant into one group. Our finding is important in general because it adds to our 
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understanding of inter-individual variability in pharmacokinetics and in particular because it 
contributes to the growing field of taxane pharmacogenomics.
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Table 1 - ABCB1 diplotype constructs from the three loci: C1236T, G2677T/A and C3435T vs. 
Clearance of unbound paclitaxel. P-value 0.12 
 # Diplotype N=93 
Nucleotide 
by phase 
Mean 
CL1(l/h) 10th2 90th2 
1 Wt/Wt 9 CGC/CGC 399 264 641 
2 Wt/full var 27 CGC/TTT 381 296 478 
3 full var/full var 18 TTT/TTT 355 291 437 
4 Other 39 ***/*** 399 282 552 
Observed number of patients assigned to the different diplotypes based on the inferred (phased) 
haplotype. Type 4 is any other combination of nucleotides (denoted ***). A linear regression 
analysis (trend-test) across diplotype 1 to 3, controlled for body surface area, age and performance 
status showed no statistical significant correlation with clearance, P-value 0.12 (uncontrolled P-value 
0.17). 
1) Geometric mean clearance of unbound paclitaxel 
2) 10th and 90th percentile observation of clearance
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Table 2 - Patient summary 
Characteristics for n=93  
evaluable patients 
Median 
 (range) 
Age (years) 60.1 (32-79.4) 
Body surface area (m
2
) 1.71 (1.27-2.37) 
Baseline biochemistry  
     Alanine aminotransferase (U/l) 22 (6-160) 
     Albumin (g/l)  42 (27 – 51) 
     Alkaline phosphatase (U/l) 87.5 (45 – 322) 
     Bilirubin (μmol/l) 5 (2-28) 
     α-acid glycoprotein (g/l) 1.08 (0.5 – 2.75) 
WHO/ECOG
1
 Performance status  N (%) 
     0 53 (57 %) 
     1 31 (33 %) 
     2 9 (10 %) 
Tumor type  
     Ovary 59 (63 %) 
     Peritoneal 20 (22 %) 
     Fallopian tube 4 (4 %) 
     Undetermined 10 (11 %) 
FIGO
2
 stage  
     I 25 (27 %) 
     II 10 (11 %) 
     III 39 (42 %) 
     IV 13 (14 %) 
     Undetermined 6 (7 %) 
Tumor grade  
     Well differentiated 15 (16 %) 
     Moderately differentiated 23 (25 %) 
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     Poorly or undifferentiated 36 (39 %) 
     Undetermined 19 (20 %) 
 
1) Eastern Cooperative Oncology Group 
2) International Federation of Gynecology and Obstetrics 
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Table 3 – Population pharmacokinetic parameter estimates for unbound paclitaxel with RSE(%)  
Parameter Estimate1 
(RSE%) 
Henningsson et 
al(27) 
Estimate2 (RSE%) 
CL3 (l/h) for PS =0-1 396 (3.2) 
343 (3.5) PS0-2 
CL (l/h) for PS=2 304 (7.8) 
V1 (l) 296 (17.8) 418 (7.1) 
Q (l/h) 156 (13.7) 188 (13) 
V2 (l) 793 (4.6) 1010 (4.2) 
BSA on V1 1.11 (49.2) 1.45 (14) 
BSA on CL 0.62 (22.6) 0.65 (22) 
BSA on V2 0.48 (28) 0.87 (18) 
Age on CL -0.0065 (31.2) n/a 
Bilirubin on CL fixed -0.012 (21) 
IIV on CL (CV%)4 17 (32) 20 (24) 
IIV on V2 (CV%)4 16 (84) 16 (37) 
IIV CrEL Binding (CV%)4 9.6 (130) 14 (31) 
 
CL, clearance of unbound paclitaxel; PS, performance status; V, compartment volume; Q, 
intercompartmental clearance; BSA, body surface area; IIV, inter-individual variability; CV%, 
coefficient of variation in %; CrEL, cremophor EL; RSE, relative standard error. 
1) Estimates for the typical individual with BSA 1.71m2, bilirubin 5 μM and age of 60.7 years 
2) Estimates for the typical individual with BSA 1.76m2 and bilirubin 5 μM 
3) CL = 396*(1+0.62*(BSA-1.71))*(1-0.012*(Bilirubin-5))*(1-0.006*(Age-60.7)) 
4) RSE% is related to the corresponding variance term, ω2 
5) Bootstrap (resampling 2 000 times): median 0.00498, 97.5% c.i.[-0.00911 : -0.00059:],  
99.55% c.i.[-0.01093 : 0.00048] 
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 Reference homozygote Heterozygote Variant homozygote 
  Gene / allele
1 Effect
2 
N
3 
CL
4
 (10th-90th) N
3 
CL
4
 (10th-90th) N
3 
CL
4
 (10th-90th) P-value
5 
SNP ID
6 
Candidate SNPs for confirmative analysis 
CYP2C8  
            1196A>G(*3) K399R 74 395 (297-490) 19 350 (238-458) 
   
0.03*(0.04) rs10509681  
ABCB1  
            1236C>T G412G 29 391 (270-569) 45 393 (299-490) 19 359 (291-437) 0.25(0.25) rs1128503  
 2677G>T/A
7 
A893S/T 26 387 (270-490) 42(GT) 396 (299-490) 20(TT) 356 (294-437) 0.20(0.26) rs2032582  
 3435C>T I1145I 11 403 (326-548) 44 387 (282-490) 38 378 (297-468) 0.83(0.43) rs1045642  
Candidate SNPs for exploratory analysis 
CYP2C8  
            792C>G(*4) I264M 86 391 (297-490) 7 321 (270-374) 
   
0.04*(0.03) rs1058930  
 15577956G>T (*1B) - 49 395 (298-552) 43 373 (291-478) 1 461 
 
0.75(0.36) rs7909236 
 15578055A>C (*1C) - 69 382 (291-478) 24 393 (300-552) 
   
0.48(0.62) rs17110453 
ABCB1  
            -1A>G - 1 458 
 
29 396 (270-592) 63 379 (297-477) 0.56(0.3) rs2214102 
 61A>G N21D 63 384 (282-490) 29 386 (298-478) 1 437 
 
0.52(0.77) rs9282564  
 1199G>A S400N 83 385 (291-490) 10 386 (322-461) 
   
0.74(0.99) rs2229109  
CYP3A4  
            24616372T>C (*1B) - 85 383 (296-490) 7 397 (270-641) 
   
0.67(0.72) rs2740574 
CYP3A5  
            219-237G>A frameshift 84 388 (297-490) 9 360 (176-726) 
   
0.30(0.36) rs776746 
SLCO1B3  
            699G>A M233I 1 326 
 
19 377 (299-481) 73 388 (291-490) 0.99(0.46) rs7311358  
 767G>C G256A 67 386 (298-481) 26 383 (291-490) 
   
0.63(0.89) rs60140950 
CYP1B1  
            1294C>G (*3) V432L 30 389 (270-530) 36 401 (298-490) 27 361 (300-470) 0.77(0.24) rs1056836  
ABCC1  
            7356253C>G - 65 394 (297-548) 27 368 (291-470) 1 332 
 
0.04(0.15) rs504348 
ABCC2  
            1249G>A V417I 67 381 (291-490) 24 396 (297-552) 2 415 (368-468) 0.21(0.39) rs2273697 
 3563T>A V1188E 87 386 (296-490) 5 370 (176-569) 
   
0.7(0.7) rs17222723 
 4544G>A C1515Y 75 389 (296-490) 3 355 (176-569) 
   
0.72(0.52) rs8187710 
ABCG2  
            421C>A Q141K 61 374 (291-478) 32 408 (315-548) 
   
0.4(0.09) rs2231142  
 34G>A V12M 87 385 (291-490) 4 395 (296-726) 
   
0.68(0.83) rs2231137  
ABCC10  
            2759T>C I920T 46 386 (297-478) 43 386 (291-548) 4 373 (326-467) 0.88(0.89) rs2125739  
Table 4 - Clearance of unbound paclitaxel as function of observed genotypes 
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Legend Table 4: 
1) Type and sequence position of nucleotide substitutions with star notation where applicable 
2) Single letter nomenclature amino acid substitution where applicable 
3) N, denotes the number of patients in the group. For some patients genotypes were unavailable 
4) Geometric mean clearance of unbound paclitaxel with 10th and 90th percentiles observed in parentheses 
5) P-values for the linear regression analysis (trend) of clearance and genotype controlled for body surface area, age and performance status with 
uncontrolled P-values shown in parentheses 
6) RS number referring to the single nucleotide polymorphism database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp) 
7) The 5 patients carrying the A allele were omitted from the analysis 
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Figure 1 - Estimates of clearance of unbound paclitaxel as function of CYP2C8*3 genotype for 93 
patients with ovarian cancer 
 
 
 
The clearance of the three patients concomitantly using a CYP3A4/5 inhibitor are marked with black 
diamonds (none carried the *3 variant). Means are indicated by the horizontal line. 
The linear regression analysis of clearance and genotype controlled for body surface area,  age and 
performance status showed that patients carrying the CYP2C8*3 variant had a statistically significant 
lower mean clearance with P-value of 0.03 (uncontrolled P-value 0.04). Wt, wild-type. 
